Yi Larson
CIK 1785987 · Chief Financial Officer · last filed 2025-06-13
Yi Larson is a Chief Financial Officer who has filed 17 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing, for OLMA, was dated Jun 13, 2025. Across all open-market trades the lifetime net is −$3.7M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
4
17
-$3.70M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OLMA | Director | — | $9.87 | — | $0 | 7 | 2025-06-13 |
| RayzeBio, Inc. (RYZB) Delisted | Director | — | $62.49 | — | $0 | 1 | 2024-02-27 |
| LianBio (LIAN) Delisted | Chief Financial Officer | 325,901 | $0.32 | $104.0K | $0 | 4 | 2023-03-31 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | EVP & Chief Financial Officer | 7,321 | $76.01 | $556.5K | -$3.70M | 5 | 2021-02-10 |
Recent Filings
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-13 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2024-06-18 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2024-02-27 | RayzeBio, Inc. (RYZB) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-06-21 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2023-03-31 | LianBio (LIAN) Delisted | Grant (A) | +325,901 | $0 | EDGAR |
| 2023-01-24 | LianBio (LIAN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-27 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2022-06-17 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2021-12-03 | LianBio (LIAN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-01 | LianBio (LIAN) Delisted | Grant (A) | — | $0 | EDGAR |